About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 384 record(s)
Req # A-2020-001788
Adverse Drug Reaction (ADR) for Naltrexone. Report number: 000924057. ADRs for Heparin. Report numbers: 000919736, 000924146. ADRs for Hydromorphone. Report numbers: E2B_03444792, E2B_03464472.Organization: Health Canada
September 2022
Req # A-2020-001910
Adverse Drug Reactions (ADRS) for Morphine. Report numbers: E2B_03507223, E2B_03533065, 000930894. ADRS for Naltrexone. Report numbers: 000927586, 000928613, 000933266. ADRS for Hydromorphone. Report numbers: E2B_03532479, 000931717. ADRS for Heparin. Report numbers: 000932425, 000932687.Organization: Health Canada
September 2022
Req # A-2021-000443
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-100534-428.Organization: Health Canada
September 2022
Req # A-2021-000445
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-117922-808, Information Technology Planned Investment Submission.Organization: Health Canada
September 2022
Req # A-2021-000654
Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: E2B_03506446, E2B_03478436, E2B_03454053, E2B_03473106, 000921901, E2B_03452165, E2B_03435813, E2B_03484777, E2B_03490021, E2B_03362614, E2B_03381864.Organization: Health Canada
September 2022
Req # A-2021-000804
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: 000929236, E2B_03412069, E2B_03288720, E2B_03296789, E2B_03334087, E2B_03293251, 000927092, E2B_03301838, E2B_03298200, E2B_03352233, E2B_03302033, E2B_03352239, E2B_03315294, E2B_03352726, E2B_03297754, E2B_03349875, E2B_03350102, E2B_03428989, 000922429, E2B_03299958.Organization: Health Canada
September 2022
Req # A-2021-000826
Adverse Drug Reaction (ADR) for PARACETAMOL. Report number: E2B_03496436.Organization: Health Canada
September 2022
Req # A-2021-001034
Adverse Drug Reactions (ADRs) for METRONIDAZOLE. Report numbers: E2B_03679537, E2B_03524775, 000930450.Organization: Health Canada
September 2022
Req # A-2021-001127
Adverse Drug Reactions (ADRs) for METOLAZONE. Report numbers: E2B_03655808, 933935, 943889.Organization: Health Canada
September 2022
Req # A-2021-001177
Adverse Drug Reactions (ADRs). Report numbers: E2B_01661780, E2B_04330549, 000963484, E2B_01698982, E2B_02666716, E2B_02126270, E2B_04286027, E2B_02261300, E2B_01423470, E2B_04306428, E2B_03467218, E2B_04309802, E2B_04301507, E2B_04309405, E2B_04310865, E2B_04284040, E2B_04304150, E2B_04355771, E2B_02274574, E2B_04283570.Organization: Health Canada
September 2022